There is provided a novel quantification method for quantifying a concentration of EAP, which is a biomarker of depression, an enzyme for quantitation, a composition for quantitation, a kit for quantitation or a sensor for quantitation. There is provided a quantification method of ethanolamine phosphate by adding oxidoreductase to a sample containing ethanolamine phosphate. A mediator may be reduced by adding the oxidoreductase, and the reduced mediator may be reacted with a reagent to determine a concentration of ethanolamine phosphate. In addition, hydrogen peroxide produced by adding the oxidase as the oxidoreductase may be reacted with a reagent to determine a concentration of the ethanolamine phosphate.

A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.

The invention relates to an in vitro or ex vivo method for differentially diagnosing a bipolar disorder and a major depressive disorder in a human patient in a need thereof presenting depressive symptoms, comprising the following steps: providing a biological sample from said patient; determining, from said biological sample, the abundance of at least one of the following cytokines TNF-α, IFN-γ, IL-6, IL-10, IL-12p40, IL-15, IL-16, IL-17A and IL-27; and diagnosing a bipolar disorder or a major depressive disorder from the determination of the abundance of the at least one of the following cytokines TNF-α, IFN-γ, IL-6, IL-10, IL-12p40, IL-15, IL-16, IL-17A and IL-27.

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.

Biomarkers and methods for screening expression levels of the biomarkers for predicting and tracking suicidality, as well as for monitoring response to a treatment for suicidal risk and for determining suicidal risk as a side-effect of an antidepressant are disclosed.

The disclosed technology enables, among other things, the identification of persons and the characterization of mental perceptions (e.g., pain, fatigue, mood) and/or intent (e.g., to perform an action) for medical, safety, home care, and other purposes. Of significance are applications that require long-term patient monitoring, such as tracking disease progression (e.g., multiple sclerosis), or monitoring treatment or rehabilitation efficacy. Therefore, longitudinal data must be acquired over time for the person's identity and other characteristics (e.g., pain level, usage of a cane). However, conventional methods of person identification (e.g., photography) acquire unnecessary personal information, resulting in privacy concerns. The disclosed technology allows measurements to be performed while protecting privacy and functions with partial or incomplete measurements, making it robust to real-world (noisy, uncontrolled) settings, such as in a person's home (whether living alone or with others).

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.

A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.

The present invention is directed to methods of probiotic selection and use based on the capability of microbial biogenic amine uptake as a method for targeted clinical and veterinary applications, including promoting health and well-being and/or treating therapeutic conditions. The present invention utilizes a microbially-focused approach for the development of drug selection and/or probiotic administration in a variety of diseases and disorders.

The disclosed technology enables, among other things, the identification of persons and the characterization of mental perceptions (e.g., pain, fatigue, mood) and/or intent (e.g., to perform an action) for medical, safety, home care, and other purposes. Of significance are applications that require long-term patient monitoring, such as tracking disease progression (e.g., multiple sclerosis), or monitoring treatment or rehabilitation efficacy. Therefore, longitudinal data must be acquired over time for the person's identity and other characteristics (e.g., pain level, usage of a cane). However, conventional methods of person identification (e.g., photography) acquire unnecessary personal information, resulting in privacy concerns. The disclosed technology allows measurements to be performed while protecting privacy and functions with partial or incomplete measurements, making it robust to real-world (noisy, uncontrolled) settings, such as in a person's home (whether living alone or with others).